Critical Limb Ischemia - Pipeline Review, H1 2017
Critical Limb Ischemia - Pipeline Review, H1 2017 BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers. We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document. We look forward to being of service to you. If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf. Phone: +44 (0)1300 321501 or Email: reportstore@bioportfolio.com 2
Critical Limb Ischemia - Pipeline Review, H1 2017 Critical Limb Ischemia - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Critical Limb Ischemia - Pipeline Review, H1 2017, provides an overview of the Critical Limb Ischemia (Cardiovascular) pipeline landscape. Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality of life and increasing survival. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Critical Limb Ischemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Critical Limb Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Critical Limb Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 12, 4 and 11 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively. Critical Limb Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia (Cardiovascular). 3
- The pipeline guide reviews pipeline therapeutics for Critical Limb Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from preregistration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Critical Limb Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Critical Limb Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Critical Limb Ischemia (Cardiovascular) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Critical Limb Ischemia (Cardiovascular). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Critical Limb Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Additional Details Publisher : Global Markets Direct Reference : GMDHC9300IDB Number of Pages : 126 Report Format : PDF Publisher Information : 4
5
Table Of Contents for Critical Limb Ischemia - Pipeline Review, H1 2017 [Report Updated: 16-05-2017] Table of ContentsList of TablesList of FiguresIntroductionGlobal Markets Direct Report CoverageCritical Limb Ischemia - OverviewCritical Limb Ischemia - Therapeutics DevelopmentPipeline OverviewPipeline by CompaniesPipeline by Universities/InstitutesProducts under Development by CompaniesProducts under Development by Universities/InstitutesCritical Limb Ischemia - Therapeutics AssessmentAssessment by TargetAssessment by Mechanism of ActionAssessment by Route of AdministrationAssessment by Molecule TypeCritical Limb Ischemia - Companies Involved in Therapeutics DevelopmentAnGes MG Incapceth Biopharma GmbHAthersys IncBiogenCell LtdCaladrius Biosciences IncCynata Therapeutics LtdHemostemix LtdHistocell SLID Pharma Co LtdIntegene International Holdings LLCJuventas Therapeutics IncKasiak Research Pvt LtdKowa Company LtdNeurofx IncPharmicell Co LtdPluristem Therapeutics IncReNeuron Group PlcSymic Biomedical IncTikoMed ABU.S. Stem Cell IncVericel CorpVESSL Therapeutics LtdViroMed Co LtdCritical Limb Ischemia - Drug ProfilesACP-01 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressAdipoCell - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressAlecmestencel-T - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressASCT-01 - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progressbeperminogene perplasmid - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressBGC-101 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressBiologic to Activate FGF2 for Critical Limb Ischemia - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressCellgram-CLI - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressCLBS-12 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressDVC-10101 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressGene Therapy for Critical Limb Ischemia - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressHC-016 - Drug ProfileProduct DescriptionMechanism Of ActionR&D Progressixmyelocel-T - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressJVS-100 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressMultiGeneAngio - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressNFx-101 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressNK-104 NP - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressPF-05285401 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressPLX-PAD - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressProtein to Agonize LRP5 and LRP6 for Critical Limb Ischemia and Myocardial Infarction - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressRefacell-CLI - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressRejuveinix - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressReN-009 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressSB-030 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressStem Cell Therapy for Cardiovacular Diseases - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressStem Cell Therapy for Critical Limb Ischemia - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressStem Cell Therapy for Critical Limb Ischemia - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressTM-700 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressTXA-302 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressVM-202 - Drug ProfileProduct DescriptionMechanism Of ActionR&D ProgressCritical Limb Ischemia - Dormant ProjectsCritical Limb Ischemia - Discontinued ProductsCritical Limb Ischemia - Product Development MilestonesFeatured News & Press ReleasesJan 17, 2017: Pluristem Receives Clearance from Germany to Initiate its Multinational Phase III Trial in Critical Limb Ischemia Targeting Early Conditional Marketing ApprovalJan 10, 2017: Pluristem's Phase III Study of PLX-PAD Cells for the Treatment of Critical Limb Ischemia Cleared by U.S. FDANov 01, 2016: Pluristem s Pivotal Phase III Critical Limb Ischemia Trial Approved by UK Regulatory AgencyOct 03, 2016: Hemostemix Announces it has been Granted two Additional Patents in the US and in CanadaSep 08, 2016: Pluristem to Conduct Symposium on PLX-PAD Potential for the Treatment of Peripheral Artery Disease at a Multinational Conference on Vascular MedicineAug 09, 2016: Pluristem s Phase III Critical Limb Ischemia Study Wins $8 Million Grant from Europe s Horizon 2020 ProgramAug 02, 2016: Pluristem Receives Positive Feedback from FDA and Gears Up for Phase III Trial of PLX-PAD in Critical Limb IschemiaJul 27, 2016: Pluristem Advances Towards Multinational Phase III Trial of PLX-PAD to Improve Recovery Following Surgery for Hip FractureJun 20, 2016: AnGes Announces Amendment to the Global Development of HGF Plasmid for Critical Limb IschemiaApr 18, 2016: Hemostemix Receives IRB Approval from the Houston Methodist Hospital Research Institute and the University of California Los AngelesApr 18, 2016: Caladrius Reaches Agreement with Japanese Regulators on Development Plan for CD34 Cell Therapy for Critical Limb IschemiaJan 22, 2016: ViroMed Publishes Results from Critical Limb Ischemia Phase II Clinical 6
StudyDec 22, 2015: Hemostemix Poised to Expand Phase-2 Clinical Trial of Lead Product ACP-01 to the United StatesDec 21, 2015: Pluristem Reaches Agreement with Japan s PMDA on Protocol for Final Trial Targeting Market Entry via Accelerated PathwayOct 05, 2015: Hemostemix to Present at 2015 Stem Cell Meeting on the MesaAppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact UsDisclaimer 7
How to Buy... Critical Limb Ischemia - Pipeline Review, H1 2017 [Report Updated: 16-05-2017] Option 1 - Online Go to our website and pay online with any major debit or credit card: Option 2 - Request a Proforma Invoice Fill in the details below, and either Scan this page and email it to us at reportstore@bioportfolio.com or Fax it to us at +44 (0)1305 791844.We will send you a Proforma Invoice and deliver your report on settlement. Your Name: Job Title: Your Email: Your Contact Phone: Company Name: Address: Post/Zip Code: Country: P.O. Number: Any Other Instructions: Pricing Options: (please tick one) $2000 Single User Price $4000 Site License Price $6000 Enterprise License Price Payment Options: (please tick one) Online Credit Card (we will email you the invoice with a payment link) Direct Wire Transfer (we will email you the invoice with our bank details) Authorising Signature: Option 3 - Phone Us on +44 (0)1300 321501 We will be delighted to give you our personal attention. 8